arrow_back Civic Audit
Share share

Medicaid VBPs for Patients Act (MVP Act)

This act allows Medicaid to pay for drugs based on how well they actually work for patients. It aims to make expensive, cutting-edge treatments more accessible while ensuring public funds are not wasted on ineffective therapies.
Key points
Drug prices can be linked to specific health outcomes achieved by the patient.
Improved access to expensive, transformative treatments like gene therapies for rare diseases.
States can receive refunds or pay less if a drug fails to meet promised health measures.
New legal protections and rules for value-based payment agreements between manufacturers and states.
article Official text account_balance Process page notifications_active Track this Bill
gavel
Status:
Introduced
Record your position for audit.
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.
Additional Information
Print number: 119_HR_7871
Sponsor: Rep. Guthrie, Brett [R-KY-2]
Process start date: 2026-03-09
System Note: Lustra is free, publicly auditable civic infrastructure, with full source code available on GitHub. You are reading sterilized legislative data, processed by our radical neutrality engine to strip political spin and retain factual mechanics. We process only official government data. Original documents remain the authoritative source, always verify them if you can.
Summarized by: gemini-flash-latest
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

MVP Act

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 119_HR_7871.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2026-03-09.

What are the main provisions?

Key points include:

  • Drug prices can be linked to specific health outcomes achieved by the patient.
  • Improved access to expensive, transformative treatments like gene therapies for rare diseases.
  • States can receive refunds or pay less if a drug fails to meet promised health measures.
  • New legal protections and rules for value-based payment agreements between manufacturers and states.
What is the specific legal status?

The current status is Introduced.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Guthrie, Brett [R-KY-2].

What is the latest detailed status?

The latest detailed status is: Introduced in House

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2026-03-10.

What is the impact of this bill?

We don't know, that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge.

CATEGORIES

Health